(PharmaNewsWire.Com, December 05, 2018 ) Schizophrenia-Disease Understanding and Treatment Algorithm According to National Institute of Mental Health, Schizophrenia is a chronic and severe mental disorder characterized by profound disruptions in thought processes, perceptions, emotional responsiveness and social interactions. It can impair functioning through the loss of an acquired capability to earn a livelihood, or the disruption of studies. The symptoms includes hallucinations, delusions and thought disorder (unusual ways of thinking), as well as reduced expression of emotions, reduced motivation to accomplish goals, motor impairment and cognitive impairment. It typically begins in late adolescence or early adulthood.
The Publisher Schizophrenia market report gives the thorough understanding of the Schizophrenia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Schizophrenia in the US, Europe, and Japan.
Top Companies Covered in this Report are: Sunovion, H. Lundbeck A/S, Minerva Neurosciences
Schizophrenia Epidemiology The Schizophrenia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Publisher report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Case, Incident Cases, Diagnosed Prevalence, Gender Specific Prevalence, and Age Specific Prevalence] scenario of Schizophrenia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027. According to World Health Organization (WHO), the data from European and North American studies show persisting disability of moderate or severe degree in about 40% of males with schizophrenia, in contrast with 25% of females
Schizophrenia Drug Chapters This segment of the Schizophrenia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The major marketed drugs approved for Schizophrenia are based on dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Rexulti (Otsuka Pharmaceutical), Seroquel (AstraZeneca) and Invega Sustenna (Janssen Pharmaceuticals) are the drugs used for the treatment of patients with Schizophrenia. Most currently approved therapies for schizophrenia are primarily directed toward positive symptoms.
Schizophrenia Market Outlook The Schizophrenia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. Key players such as Sunovion, H. Lundbeck A/S, Minerva Neurosciences, and many others are involved in developing therapies for Schizophrenia. Expected launch of emerging therapies such as SEP-363856 (Sunovion), Lu AF35700 (H. Lundbeck A/S), Roluperidone (Minerva Neurosciences), and other compelling therapies are expected to increase the market size of Schizophrenia in upcoming years.
Schizophrenia Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Schizophrenia Report Insights -Patient Population -Therapeutic Approaches -Pipeline Analysis -Market Size and Trends -Market Opportunities -Impact of upcoming Therapies
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
